Abstracts Archive - Page 710 of 2425 - ACR Meeting Abstracts

Abstract Number: 1236 • ACR Convergence 2020
Association Between Change in Health Assessment Questionnaire Disability Index and Treatment Response in Patients with Rheumatoid Arthritis in Tocilizumab Clinical Trials
Sebastian Unizony¹, Joseph Dang², Jian Han³, Margaret Michalska² and Jennie H. Best², ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, Inc., South San Francisco, ³Genentech, South San Francisco, CA
Background/Purpose: The efficacy and safety of intravenous (IV) and subcutaneous (SC) tocilizumab (TCZ) in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and as monotherapy…
Abstract Number: 1242 • ACR Convergence 2020
Transcranial Direct Current Stimulation for Fatigue in Patients with Sjogren’s Syndrome: A Randomized, Double-blind Pilot Study
Ana Pinto¹, Sara Piva², Alexia Vieira³, Samantha Gomes³, Aline Rocha⁴, Daniela Tavares³, Marcia Santana³, Cristiane Carlesso⁵, Adagmar Andriolo³, Fania Santos⁶, Felipe Fregni⁷ and Virginia Trevisani³, ¹Universidade Federal do Amapa, Sao Paulo, Brazil, ²Department of Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ³Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ⁴Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ⁵University of Pittsburgh, Pittsburgh, ⁶Universidade Federal de Sao Paulo, Sao Paulo, Saint Helena, ⁷Harvard Medical School, Cambridge, MA
Background/Purpose: Transcranial direct-current stimulation (tDCS) has shown promise to decrease fatigue. However, it has never been examined in primary Sjogren Syndrome (pSS). We aimed to assess…
Abstract Number: 1241 • ACR Convergence 2020
Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Tofacitinib or Biological DMARDs in Real Life Conditions in Two Latin America Countries
Hugo Madariaga¹, Juan Reyes², Magda Gutierrez³, Dario Ponce de Leon⁴, Tatjana Lukic⁵ and Luisa Amador², ¹Centro Medico CEEN, Arequipa, Arequipa, Peru, ²Pfizer, Bogota, Cundinamarca, Colombia, ³Pfizer, Santiago, Region Metropolitana, Chile, ⁴PFIZER, LIMA, Peru, ⁵Pfizer Inc, New York, NY
Background/Purpose: The objective of this study was to describe the efficacy, safety and patient reported outcomes in Latin-American patients with Rheumatoid Arthritis (RA) treated with…
Abstract Number: 1247 • ACR Convergence 2020
Features of Childhood Sjogren’s Syndrome: A Literature Review Based Cohort
Achille Marino¹, Micol Romano², Teresa Giani³, Carla Gaggiano⁴, Stefania Costi⁵, Revika Singh⁶, Jay Mehta⁷, Scott Lieberman⁸ and Rolando Cimaz⁹, ¹Department of Pediatrics, Desio Hospital, Milan, ²ASST Gaetano Pini-CTO Institute, Milan, Italy, Milan, Italy, ³AOU Meyer, Florence, Italy, ⁴Department of Pediatrics, University of Siena, Siena, Italy, Siena, Italy, ⁵University of Milan, Milan, Italy, Milan, Italy, ⁶Northwestern University, Evanston, IL, ⁷Division of Rheumatology, Children's Hospital of Philadelphia, Philadelphia, USA, Philadelphia, PA, ⁸Department of Pediatrics, University of Iowa, Iowa City, US, Iowa City, IA, ⁹ASST Gaetano Pini-CTO Institute and Università degli Studi di Milano, Milan, Italy, Milan, Italy
Background/Purpose: Sjogren’s syndrome (SS) is an autoimmune chronic disease characterized by inflammation of exocrine glands, but it can affect other organs as well.This study aims…
Abstract Number: 1249 • ACR Convergence 2020
The Impact of Anti-Ro Antibodies on the Pregnancy Outcome in Relation to Maternal Disease Presentation: A Descriptive Analysis of 231 Pregnancies
Eman Satti¹, Nawal Hadwan¹, Hadil Ashour¹, Rawan Saleh¹, Fiaz Alam¹, Omar Alsaed¹ and Samar Al Emadi¹, ¹Hamad medical corporation, DOHA, Qatar
Background/Purpose: Anti-Ro antibody positivity is linked to adverse fetal outcomes like congenital heart block CHB (2%) and neonatal lupus. The incidence of CHB increases to…
Abstract Number: 1244 • ACR Convergence 2020
Clinical Characteristics and Outcomes in Patients with Primary Sjögren’s Syndrome-Associated Interstitial Lung Disease
Joanna Marco¹, Gregory Gardner¹ and Nishant Gupta², ¹University of Washington, Seattle, WA, ²University of Cincinnati, Cincinnati
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a chronic autoimmune exocrinopathy that features interstitial lung disease (ILD) in up to 16% of patients. The clinical characteristics…
Abstract Number: 1239 • ACR Convergence 2020
Peripheral Protein Biomarker Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis
Peter Taylor¹, Amer Mirza², Bryan Downie², Jinfeng Liu², Rachael Hawtin² and Emon Elboudwarej², ¹Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster City
Background/Purpose: Filgotinib (FIL), an oral selective JAK1 inhibitor, has shown efficacy and safety in phase 3 studies in adults with moderately-to-severely active rheumatoid arthritis (RA),…
Abstract Number: 1252 • ACR Convergence 2020
Ultrasound-guided Parotid Gland Biopsy in Cadavers Performed by Rheumatologists – an OMERACT Ultrasound Working Group Study
Nevsun Inanc¹, Sandrine Jousse-Joulin², Kerem Abacar³, Leyla Cinel⁴, Maria D’Agostino⁵, Esperanza Naredo⁶, Alojzija Hocevar⁷, Stephanie Finzel⁸, Lene Terslev⁹, Annamaria Iagnocco¹⁰, Petra Hanova¹¹, Wolfgang Schmidt¹², Gonca Mumcu¹³, Ümit S. Şehirli¹⁴ and George A. Bruyn¹⁵, ¹Marmara University, School of Medicine, Division of Rheumatology, istanbul, Turkey, ²Rheumatology Department, Cavale Blanche Hospital and Brest Occidentale University, Brest, France, ³Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey, ⁴Marmara University, School of Medicine, Division of Pathology, Istanbul, Turkey, ⁵Université Versailles Saint Quentin, Ambroise Paré Hospital, Paris, France, ⁶Department of Rheumatology, Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz, IIS Fundación Jiménez Díaz and Universidad Autónoma de Madrid, Madrid, Spain, ⁷University Medical Center, Rheumatology, Ljubljana, LJUBLJANA, Slovenia, ⁸Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, ⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup., Copenhagen, Denmark, ¹⁰Università degli Studi di Torino, Academic Rheumatology Centre, Turin, Italy, ¹¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ¹²Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ¹³Marmara University School of Health Sciences, Health Management, Istanbul, Istanbul, Turkey, ¹⁴Marmara University, School of Medicine, Anatomy, Istanbul, Turkey, ¹⁵Rheumatology, Reumakliniek Lelystad, Lelystad, Netherlands
Background/Purpose: With the diagnostic capability of the parotid gland biopsy similar to minor salivary gland biopsy in Sjögren’s syndrome, the parotid gland biopsy may also…
Abstract Number: 1255 • ACR Convergence 2020
Sjӧgren’s Syndrome Minor Salivary Gland Mesenchymal Stromal Cells Derived Deploy Intact Immune Plasticity and Display Myofibroblast-Like Properties
Sara McCoy¹, Jayeeta Giri¹, Rahul Das¹, Pradyut Paul¹, Andrea Pennati¹, Maxwell Parker¹, Yun Liang¹ and Jacques Galipeau¹, ¹University of Wisconsin, Madison
Background/Purpose: Primary Sjӧgren’s syndrome (pSS) is the second most common systemic autoimmune disease with hallmark features of severe ocular and oral sicca, leading to reduced…
Abstract Number: 1256 • ACR Convergence 2020
Mast Cells Contribute to the Development of Sialadenitis Associated with Sjögren’s Syndrome via Inducing Tissue Fibrosis by TGFβ Production
Shinjiro Kaieda¹, Kyoko Fujimoto¹ and Hiroaki Ida¹, ¹Kurume University School of Medicine, Kurume, Japan
Background/Purpose: Mast cells have been implicated in many immune-inflammatory disorders. They mediate a variety of inflammatory and fibrotic conditions, but their role in sialadenitis in…
Abstract Number: 1251 • ACR Convergence 2020
Assessing the Construct Validity of the Novel OMERACT Ultrasound Scoring System for Salivary Glands Target Lesions by Comparison with MRI in Patients with Sjögren’s Syndrome – An OMERACT Ultrasound Working Group Exercise
Nevsun Inanc¹, Sandrine Jousse-Joulin², Kerem Abacar³, Çagatay Cimşit⁴, Canan Cimşit⁴, Maria D’Agostino⁵, Esperanza Naredo⁶, Alojzija Hocevar⁷, Stephanie Finzel⁸, Lene Terslev⁹, Annamaria Iagnocco¹⁰, Petra Hanova¹¹, Wolfgang Schmidt¹², Gonca Mumcu¹³ and George A. Bruyn¹⁴, ¹Marmara University, School of Medicine, Division of Rheumatology, istanbul, Turkey, ²Rheumatology Department, Cavale Blanche Hospital and Brest Occidentale University, Brest, France, ³Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey, ⁴Marmara University School of Medicine, Radiology, Istanbul, Istanbul, Turkey, ⁵Université Versailles Saint Quentin, Ambroise Paré Hospital, Paris, France, ⁶Department of Rheumatology, Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz, IIS Fundación Jiménez Díaz and Universidad Autónoma de Madrid, Madrid, Spain, ⁷University Medical Center, Rheumatology, Ljubljana, LJUBLJANA, Slovenia, ⁸Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, ⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup., Copenhagen, Denmark, ¹⁰Università degli Studi di Torino, Academic Rheumatology Centre, Turin, Italy, ¹¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ¹²Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ¹³Marmara University School of Health Sciences, Health Management, Istanbul, Istanbul, Turkey, ¹⁴Rheumatology, Reumakliniek Lelystad, Lelystad, Netherlands
Background/Purpose: Imaging techniques such as salivary gland ultrasound and magnetic resonance imaging (MRI) are able to diagnose primary Sjögren syndrome (pSS) patients with high sensitivity…
Abstract Number: 1262 • ACR Convergence 2020
Single LAC Positivity versus Double and Triple Positivity for Thrombosis in SLE
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose:Antiphospholipid syndrome (APS) is classified as the development of venous and/or arterial thromboses, and pregnancy morbidity, in the presence of antiphospholipid antibodies (aPL); lupus anticoagulant,…
Abstract Number: 1259 • ACR Convergence 2020
The Impact of Antimalarial Agents on Traditional and Non-traditional Cardiovascular Markers in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis
Claudia Mendoza-Pinto¹, Mario Garcia-Carrasco¹, Pamela Munguía-Realpozo², Ivet Etchegaray-Morales² and Socorro Mendez-Martínez¹, ¹Instituto Mexicano del Seguro Social, Puebla, Puebla, Mexico, ²Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, Mexico
Background/Purpose: Cardiovascular morbidity and mortality is a well-established problem in patients with systemic lupus erythematosus (SLE). Hydroxychloroquine (HCQ) has been seen as a potential atheroprotective…
Abstract Number: 1254 • ACR Convergence 2020
Lack of Efficacy of Early Treatment with Hydroxychloroquine in a Group of Hispanics with Primary Sjögren’s Syndrome
Ariana González-Meléndez¹, Patricia Jordán-González¹, Ricardo Gago-Piñero¹, Noemí Varela-Rosario¹, Naydi Pérez-Ríos¹ and Luis Vilá¹, ¹University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Treatment of primary Sjögren’s syndrome (pSS) with hydroxychloroquine (HCQ) has been evaluated in the past but with conflicting results regarding its efficacy. While earlier…
Abstract Number: 1146 • ACR Convergence 2020
Pilot Study of an Internet-Based Pain Coping Skills Training Program for Patients with Systemic Lupus Erythematosus
Kelli Allen¹, Tyler Beuchamp², Rebecca Cleveland³, Kimberlea Grimm¹, David Hu¹, Katie Huffman¹, Frances Keefe⁴, Julie Norfleet¹, Christine Rini⁵, Andres Santana¹, Shruti Saxena Beem⁶ and Saira Sheikh⁷, ¹University of North Carolina at Chapel Hill, Chapel HIll, NC, ²Medical College of Georgia, Augusta, GA, ³University of North Carolina, Chapel Hill, NC, ⁴Duke University Medical Center, Durham, NC, ⁵Northwestern University, Chicago, IL, ⁶University of North Carolina at Chapel Hill, Chapel Hill, ⁷University of North Carolina Thurston Arthritis Research Center, Chapel Hill
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) have increased symptoms of fatigue, chronic pain, depression and anxiety, which are associated with negative impacts on quality…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].